WGS 118.26 ▲ 0.76% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    GeneDx Corp.

    NASDAQ: WGS · Real-Time Price · USD
    118.26
    0.89 (0.76%)
    At close: Oct 03, 2025, 3:59 PM
    118.35
    0.08%
    After-hours: Oct 03, 2025, 07:15 PM EDT
    0.76%
    Bid 113
    Market Cap 3.4B
    Revenue (ttm) 362.32M
    Net Income (ttm) 1.41M
    EPS (ttm) 0.08
    PE Ratio (ttm) 1478.25
    Forward PE 47.33
    Analyst Buy
    Dividends n/a
    Ask 123
    Volume 639,935
    Avg. Volume (20D) 731,295
    Open 117.55
    Previous Close 117.37
    Day's Range 116.23 - 121.57
    52-Week Range 46.62 - 136.00
    Beta 2.04
    Ex-Dividend Date n/a

    About WGS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol WGS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for WGS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    GeneDx Corp. is scheduled to release its earnings on Oct 28, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    +12.78%
    GeneDx Holdings shares are trading higher after We... Unlock content with Pro Subscription
    2 months ago
    +8.09%
    GeneDx shares are trading higher after the company raised FY25 sales guidance above estimates.
    news image

    4 days ago · businesswire.com

    GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the launch of BEACONS, the nation's first multi-state genomic newborn screening initiative.

    news image

    5 days ago · businesswire.com

    GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the appointment of Lisa Gurry as Chief Business Officer, effective immediately.

    news image

    1 week ago · businesswire.com

    GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity...

    news image

    2 weeks ago · zacks.com

    3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

    GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

    news image

    2 weeks ago · businesswire.com

    GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors.

    news image

    1 month ago · zacks.com

    Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates?

    GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    news image

    1 month ago · zacks.com

    Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?

    GeneDx Holdings Corp. (WGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, WGS's 50-day simple moving average broke out above its 2...

    news image

    2 months ago · businesswire.com

    GeneDx to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.

    news image

    2 months ago · seekingalpha.com

    GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth

    GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement ra...

    news image

    2 months ago · fool.com

    Why GeneDx Holdings Stock Crushed It Again Today

    GeneDx (WGS 12.78%) shareholders are having quite a spectacular week, and it's not over yet. On Wednesday, the company's stock soared again, notching a nearly 13% pop after the previous day's 8%-plus ...

    Add to Watchlist